FDA Issues Draft Guidance on Targeted Drug Therapies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Issues Draft Guidance on Targeted Drug Therapies


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA issued a draft guidance for industry comment that contains proposed policy for diagnostic tests used with targeted drug therapies (i.e., personalized medicine). Companion diagnostics are used to help healthcare professionals determine whether a patient with a particular disease or condition should receive a particular drug therapy or how much of the drug to give, according to the press release about the guidance. The draft guidance discusses the agency’s plans for how it will review a companion diagnostic and its corresponding therapy.

The draft guidance defines a companion diagnostic and its use. According to the release, for example, looking for a specific gene amplicfication in a patient that may predict whether a drug would benefit that patient. Herceptin (trastuzumab), approved in 1998, for instance, targets HER2 gene amplification or HER2 protein over-expression in potential breast cancer patients. Herceptin “was approved with a companion test and today testing is routinely performed on women diagnosed with breast cancer to help health care professionals determine whether or not the patient should receive” it, says the release.

The draft guidance calls for early engagement between FDA and manufacturers so that the agency’s expectations can be included in development plans, and states that FDA will aim to conduct simultaneous reviews of a drug or biologic therapy and its corresponding companion diagnostic. The document also notes instances in which the agency may approve a targeted medicine in the absence of a cleared or approved companion diagnostic (e.g., in cases where the therapy is intended to treat a serious or life-threatening disease or condition for which there is no available or satisfactory treatment and when the potential benefits outweigh the risks of not having a cleared or approved companion diagnostic, states the release).

Comments on the draft guidance are due Sept. 12, 2011.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here